The Week in Swiss Startups (20-24.11.2023) - Week #48
The fourth week of Nov '23 features 8 startups and 2 exits. T3 Pharma acquired for up to CHF 450M - Congrats! Three jobs in the Swiss startup/VC ecosystem!
Hi there,
The Swiss startup ecosystem received a significant boost last week as the biotech/pharma industry demonstrated its unwavering strength. Following Amal Therapeutics' acquisition for up to €425M in 2019, Boehringer Ingelheim has now acquired Basel-based T3 Pharma for up to CHF 450M.
This marks the second-largest exit in 2023 (source: dealroom.co):
VectivBio (Biotech) acquired by Ironwood Pharmaceuticals for ~$1B
T3 Pharma (Biotech) acquired by Boehringer Ingelheim for up to CHF450M
Metaco (Fintech) acquired by Ripple for $250M
These acquisitions underscore the Swiss biotech/pharma industry's appeal as a global hub for innovation and value creation!
My recent newsletter generated significant interest, particularly for the insightful "Future of VCs" report. ICYMI, you’ll find it here.
Stay tuned!
Gian
P.S.: Do you want to support/sponsor the weekly newsletter? Discover your options here!
B2B SaaS
Transcality: CHF 100k - Convertible loan
B2C
IRISgo: CHF 10k - Award
Engineering
Deeplight: CHF 100k - Loan
Foodtech
ProSeed: CHF 100k - Loan
Medtech
Alivion: CHF 3.8M - Equity + Non-dilutive grant
Biped: CHF 1.3M
MYNERVA: CHF 100k - Award
Deep Breath Intelligence: CHF 15k - Award
—
Exit
Boehringer Ingelheim acquires T3 Pharma for up to CHF 450M
Danstar Ferment acquires Evolva for CHF 20M
—
Swisspreneur Podcast
Listen to Sophie Lamparter, co-founder of DART Ventures: Fundraising in 2023 - EP #357
—
Jobs in Swiss VCs and startups
Technology Venture Capital Analyst (6 months internship) - VI Partners
Senior Corporate Partnership Manager - Plug and Play Tech Center
Thank you for reading. If you liked it, share it with your friends, colleagues, and everyone interested in the Swiss startup ecosystem. Subscribe below and follow me on LinkedIn to never miss The Week in Swiss Startups again.